Acta Pharmaceutica Sinica B
|
2026, 16(6): 3540-3581
• Reviews •
Engineered extracellular vesicles for combinatorial cancer therapy and imaging
Full
Anita S. La'ah, Nashmin Fayazi Hosseini, Choongmo Kang, Amirhossein Ahmadieh-Yazdi, Mohsen Sheykhhasan, Piao Yang, Armita Ghotaslou, Hamed Manoochehri, Yun Suk Huh, Heemin Kang, Pooyan Makvandi
Affiliations
doi: 10.1016/j.apsb.2026.03.054
Outline
Cancer treatment has advanced significantly over the past few decades, resulting in improved patient survival outcomes. However, challenges like drug resistance, off-target effects, and systemic toxicity continue to persist. These underscore the importance of modified extracellular vesicles (EVs) as a versatile and innovative platform for delivering combination therapies for cancer. This review highlights the utilization of biocompatible engineered EVs to inhibit cancer progression with reduced side effects. Further, outlining the promising approach to cancer treatment through combination therapies and imaging-guided strategies. Additionally, this review explored the biogenesis and various sources of EVs, which provides clear insights into future directions.
Modified extracellular vesicles
/
Cancer diagnosis
/
Cancer therapy
/
Imaging-guided therapy
/
Gene therapy
/
Immunotherapy
/
Drug delivery
/
Combination therapy
Anita S. La'ah, Nashmin Fayazi Hosseini, Choongmo Kang, Amirhossein Ahmadieh-Yazdi, Mohsen Sheykhhasan, Piao Yang, Armita Ghotaslou, Hamed Manoochehri, Yun Suk Huh, Heemin Kang, Pooyan Makvandi.
Engineered extracellular vesicles for combinatorial cancer therapy and imaging[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(6)
: 3540
-3581
.
DOI: 10.1016/j.apsb.2026.03.054
Year 2026 volume 16 Issue 6
PDF
6
3
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.03.054
- Receive Date:2025-04-23
- Online Date:2026-09-17